By Gábor Heltovics, Former CEO, Druggability Technologies
Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, former CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT-46 product using integrated services across Quotient’s network of harmonized development and manufacturing sites in the UK and US.
DRGT is a specialty pharma company developing an array of drugs in diverse indications with the objective of achieving measurable and meaningful improvement in their clinical utility. The company uses its proprietary platform to screen and select Super-API compositions and its portfolio contains over 30 preclinical and clinical stage compounds.